Over the last decade or so, there has been a paradigm shift in the oncologic care of patients
with a range of solid tumour and haematologic malignancies, away from traditional cytotoxic …

Simple Summary Immune-checkpoint inhibitors (ICIs) are increasingly used in the treatment
of cancer, but they cause immune-related adverse events (irAEs) in around 40% of patients …

Abstract Purpose of Review In the past decade, immune checkpoint inhibitors (ICIs) have
revolutionized the field of cancer treatment. With the continuing rise in the number of cancer …

In the 20th century, research focused on cholesterol and lipoproteins as the key mechanism
in establishing atherosclerotic cardiovascular disease (ASCVD). Given that some studies …

Background There are limited data on the occurrence, associations and outcomes of
pericardial effusions and pericarditis on or after treatment with immune checkpoint inhibitors …

Background The use of immune checkpoint inhibitors (ICIs) in cancer treatment has led to an
increase in immune-related adverse events (irAEs), which can cause treatment …

Background Checkpoint inhibitor-related pneumonitis (CIP) is a potentially fatal immune-
related adverse event that occurs during treatment with immune checkpoint inhibitors (ICIs) …

The broad application of immune checkpoint inhibitors (ICIs) has led to significant gains in
cancer outcomes. By abrogating inhibitory signals, ICIs promote T cell targeting of cancer …

Background Peripheral blood-based biomarkers (PBB) predicting response, survival and
immune-related adverse events (irAEs) in patients with advanced non-small cell lung cancer …

Dilated cardiomyopathy (DCM) is a cardiac condition with structural and functional
impairment, where either the left ventricle or both ventricular chambers are enlarged …